Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lucid Diagnostics Inc.

NASDAQ: LUCD · Industrial Applications and Services · 5 alerts · CIK 1799011

Share price
$0.3978Close, Nov 16
Market cap
$82.3M
Shares outstanding
206.98MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lucid Diagnostics Inc. filings on SEC EDGAR ↗

8:11 AM ET 10-Q
Financial Results

Lucid Diagnostics Q3 2026 Results: Net Loss of $6.68M, Loss Narrows

Lucid Diagnostics reported a net loss of $6.7 million for the quarter ended September 30, 2026, an improvement from the $10.4 million loss in the prior year period. Total revenue remained flat year-over-year at $1.2 million, while the company significantly reduced its total liabilities from $29.5 million at year-end 2025 to $21.9 million.

Key figure
Net loss $6.68M
8:05 AM ET 8-K
Financial Results

Lucid Diagnostics Financial Results

Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.

“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer

“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.